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Abstract  
Recent findings indicate that prevalent human carcinomas overexpress the 
mitochondrial ATPase Inhibitory Factor 1 (IF1). Overexpression of IF1 inhibits the 
synthase activity of the mitochondrial H+-ATP synthase and plays a crucial role in 
metabolic adaptation of cancer cells to enhanced aerobic glycolysis. Herein, we 
demonstrate that IF1 overexpression in colon cancer cells triggers mitochondrial 
hyperpolarization and the subsequent production of superoxide radical, a reactive 
oxygen species (ROS). ROS are required to promote the transcriptional activation of the 
NFκB pathway via phosphorylation-dependent IκBα degradation. Activation of NFκB 
results in a cellular adaptive response that includes proliferation and Bcl-xL mediated 
resistance to drug-induced cell death. Quenching the mitochondrial production of ROS 
prevents the activation of NFκB and abolishes the IF1-mediated cellular adaptive 
response. Overall, our findings provide evidence linking the activity of a mitochondrial 
protein with retrograde signaling to the nucleus to promote cellular proliferation and 
survival.  
 
 
Highlights: 
1.- IF1-mediated inhibition of the H+-ATP synthase activates NFκB via ROS signaling. 
2.- IF1 signals metabolic reprogramming, proliferation, invasion and survival.  
3.- IF1-mediated overexpression of Bcl-xL confers apoptotic resistance. 
4.- IF1 switches mitochondrial activity from a tumor suppressor to a tumor promoter.  
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Introduction  
The enhanced aerobic glycolysis of tumors (Cuezva et al., 2009; Vander Heiden 
et al., 2009) is a phenotypic trait acquired by cancer cells in their progression to 
malignancy (Hanahan and Weinberg, 2011; Hu et al., 2011). The boost in glucose 
consumption is required to fuel the pentose phosphate and glycolytic pathways which 
provide the NADPH and metabolic intermediates needed as building blocks for the 
biosynthesis of nucleic acids, proteins and the phospholipids required for proliferation 
(Formentini et al., 2010; Frezza and Gottlieb, 2009). Glutamine is also utilized by 
cancer cells to replenish with carbon skeletons the TCA cycle (Frezza and Gottlieb, 
2009). In order to regenerate NAD+, aerobic glycolysis produces large amounts of 
lactate which is secreted from the cell to favor metastasis and angiogenesis (Gatenby 
and Gillies, 2004). Several mechanisms directly promoting glycolysis, inhibition of 
mitochondrial function or both have been proposed, aiming to explain the metabolic 
hallmark of cancer cells and tumors (for review see (Cairns et al., 2011; Formentini et 
al., 2010; Frezza and Gottlieb, 2009)). However, the mitochondrial contribution to the 
enhanced aerobic glycolysis of cancer cells has been questioned (Dang, 2010; Funes et 
al., 2007; Li et al., 2005). In any case, some properties of cancer cells cannot be 
explained only by mutations. In fact, it is accepted that the tumor microenvironment 
(Cairns et al., 2011; Nyberg et al., 2008) and other epigenetic events (Iacobuzio-
Donahue, 2009) contribute to cancer development and its behavior.  
A master regulator of energetic metabolism is the mitochondrial H+-ATP 
synthase, a reversible engine of oxidative phosphorylation that catalyzes the synthesis 
of ATP using as driving force the proton gradient generated by the respiratory chain 
(Boyer, 1997). Oxidative phosphorylation is also required for efficient execution of cell 
death (Dey and Moraes, 2000; Matsuyama et al., 1998; Santamaria et al., 2006) and 
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cells that are unable to perform oxidative phosphorylation and rely heavily on aerobic 
glycolysis have an apoptotic-resistant phenotype (Dey and Moraes, 2000; Santamaria et 
al., 2006). Conversely, activation of oxidative phosphorylation prevents tumor 
development (D'Errico et al., 2011; Schulz et al., 2006). The catalytic β-F1-ATPase 
subunit of the H+-ATP synthase carries out the synthesis or hydrolysis of ATP upon 
changes in the physiological conditions of the cell. Genomic (Sheffer et al., 2009), 
transcriptomic (Lu et al., 2007; Sanchez-Arago et al., 2010), proteomic (Cuezva et al., 
2002; Cuezva et al., 2009) and functional studies (Holm et al., 1995; Lopez-Rios et al., 
2007) in prevalent human carcinomas indicate that repressed bioenergetic activity of 
mitochondria is involved in tumor progression. Likewise, a lower bioenergetic activity 
of mitochondria is also linked to chemotherapy resistance (Li et al., 2010; Santamaria et 
al., 2006; Shin et al., 2005). Masking the translation of β-F1-ATPase mRNA through 
the binding of specific mRNABPs onto the mRNA (Ortega et al., 2010) or by silencing 
of the ATP5B gene promoter (Li et al., 2010) is known to affect the mitochondrial 
content of β-F1-ATPase in human cancer. Moreover, metabolic reprogramming of 
tumors also encompass the inhibition of the H+-ATP synthase activity through the 
overexpression of the ATPase Inhibitory Factor 1 (IF1) (Sanchez-Cenizo et al., 2010), 
which is a physiological inhibitor of the mitochondrial synthase.  
   The biological relevance of IF1 in human pathology is largely unknown 
(Campanella et al., 2008; Jennings et al., 1991) and specifically in the cancer field 
(Sanchez-Cenizo et al., 2010). In this study, we have addressed the mechanisms and 
signaling pathway by which IF1 could participate in the biology of cancer cells. 
Remarkably, we illustrate that a ROS-mediated retrograde response generated in 
mitochondria as a result of IF1 interference with oxidative phosphorylation switches on 
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proliferation, invasion and cell survival. The IF1-mediated adaptive response of cancer 
cells is mediated by the activation of the canonical NFκB pathway.   
 
Results 
IF1 is overexpressed in colon cancer and regulates energy metabolism of 
HCT116 cells. As revealed by immunohistochemistry, and in agreement with previous 
findings (Sanchez-Cenizo et al., 2010), IF1 is highly overexpressed in mitochondria 
(see punctuate cytoplasmic staining in right panel of Figure 1A) of human colon 
carcinomas (Figure 1A) when compared to the normal tissue (Figure 1B). The 
overexpression of IF1 in HCT116 cells (Figure 1C) resulted in decreased oxidative 
phosphorylation (OSR) (Figure 1D), mitochondrial hyperpolarization (Figure 1E) and a 
concurrent enhancement of the rate of aerobic glycolysis (Figure 1F) in agreement with 
previous findings in other cells (Sanchez-Cenizo et al., 2010). Likewise, siRNA-
mediated silencing of IF1 in HCT116 cells (Figure 1C) promoted an increase in 
oxidative phosphorylation (Figure 1D) and a reduction of the rates of aerobic glycolysis 
(Figure 1F) with marginal effect on the mitochondrial membrane potential (ΔΨm) 
(Figure 1E).  
Basal cellular ATP concentrations were not affected by the regulated expression 
of IF1 (Figure 1G). However, the inhibitory effect of IF1 on the synthase activity of the 
H+-ATP synthase was further demonstrated by the significant drop in ATP content 
when aerobic glycolysis of the cells was inhibited with 2-deoxyglucose (2DG) in IF1 
overexpressing cells (Figure 1H). Likewise, the silencing of IF1 promoted a relevant 
increase in ATP content when glycolysis was inhibited (Figure 1H). Treatment of the 
cells with oligomycin indicated that oxidative phosphorylation provides most of the 
ATP determined in the presence of 2DG (Figure 1H), thus supporting that the IF1-
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mediated changes in respiration are linked to the production of ATP by the H+-ATP 
synthase. These findings indicate that IF1 is used by cancer cells to inhibit the activity 
of H+-ATP synthase to favor the switch of energy metabolism toward aerobic glycolysis 
(Sanchez-Cenizo et al., 2010).  
IF1 regulates the rates of cellular proliferation and invasion. We studied the 
role of the expression level of IF1 in the rate of proliferation of HCT116 cells by 
assessing the incorporation of 5-ethynyl-2’-deoxyuridine (EdU) into DNA (Figure 2A). 
IF1 overexpression significantly augmented the rate of DNA replication when compared 
to control cells (Figure 2A). On the contrary, siRNA-mediated silencing of IF1 resulted 
in a lower rate of cellular proliferation when compared to control (Figure 2A). 
Moreover, the over-expression of IF1 increased cell invasiveness when compared to 
controls (Figure 2B) whereas its silencing significantly reduced invasion (Figure 2B). 
These results suggest a role for IF1 in switching on a mitochondrial retrograde signal to 
the nucleus (Butow and Avadhani, 2004). 
IF1 regulates the cell death response to toxic agents. Overexpression of IF1 
significantly diminished the percentage of dead cells (sub-G0) after treatment with 
10µM 5-fluorouracil (5FU) or 1µM staurosporine (STS) (Figure 2C). On the contrary, 
downregulation of IF1 significantly augmented the percentage of dead cells in response 
to 5FU- or STS-treatment when compared to their matched controls (Figure 2D). 
Similar results were obtained by determining the percentage of pyknotic nuclei in 
ToPro3-stained cells (see supplementary Figure S1), supporting a role for IF1 in 
controlling the fate of cancer cells. 
IF1 controls the release of apoptogenic molecules from mitochondria. 
Consistent with the role of IF1 in cell death (Figure 2C and D), the exposure of 
phosphatidylserine at the plasma membrane was significantly reduced (Figure 3A, left 
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panel) or increased (Figure 3A, right panel) in HCT116 cells treated with STS when IF1 
was over-expressed or silenced, respectively. IF1 overexpression in HCT116 cells was 
not able to prevent the rapid fragmentation of the mitochondrial reticulum after STS 
treatment but ameliorated the swelling of mitochondria (Supplementary Figure S2). On 
the other hand, IF1 downregulation in HeLa and T47D cells (both expressing high 
levels of IF1 (Sanchez-Cenizo et al., 2010)) aggravated the fragmentation and swelling 
of mitochondria after STS treatment (Supplementary Figure S2). Moreover, we noted 
that the loss of AIF immunoreactivity in mitochondria after STS treatment was delayed 
in HCT116 cells overexpressing IF1 when compared to controls (Figure 3B). 
Conversely, siRNA-mediated silencing of IF1 in HeLa cells accelerated the release of 
AIF after STS treatment (Figure 3C), supporting a role for IF1 in regulating 
mitochondrial-geared apoptosis (Figure 3A). Overall, the effects of IF1 overexpression 
on HCT116 cells mimicked the effects of oligomycin in delaying apoptosis (Matsuyama 
et al., 1998; Santamaria et al., 2006), further supporting a role for the activity of the H+-
ATP synthase in signaling the efficient execution of cell death. 
Overexpression of IF1 generates a mitochondrial ROS signal. Inhibition of the 
activity of the H+-ATP synthase, mediated either by treatment of the cells with the 
ATPase inhibitor oligomycin (Sanchez-Cenizo et al., 2010) or by the overexpression of 
IF1 (Sanchez-Cenizo et al., 2010) (and see Figure 1E), promotes mitochondrial 
hyperpolarization due to the interruption of the backflow of H+ into the matrix. In this 
situation, mitochondria produce the superoxide radical (Brand et al., 2004). 
Consistently, we observed that IF1 upregulation in HCT116 cells triggered a significant 
increase in the production of superoxide (Figure 4A). The mitochondrial scavenger 
MitoQ (MQ) (Kelso et al., 2001) was able to quench superoxide production in IF1 
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overexpressing cells (Figure 4A) as well as to ameliorate basal mitochondrial ROS 
levels in controls (Figure 4A).  
One of the targets of oxygen radicals is the covalent modification of cellular 
proteins. Indeed, a significant increase in the carbonylation of specific cellular proteins 
was noted in HCT116 cells overexpressing IF1 when compared to controls (Figure 4B 
and 4C). Remarkably, incubation of the cells with MQ diminished the IF1-triggered 
carbonylation of these proteins (Figure 4B and 4C). Interestingly, the overexpression of 
IF1 did not affect cellular hydrogen peroxide levels or the GSH/GSSG ratio (see 
Supplemental Figure S3) supporting that the IF1-mediated superoxide signal is of mild 
intensity and localized in mitochondria. 
Cellular adaptive response to the regulated expression of IF1. IF1 was either 
overexpressed or silenced in HCT116 cells (Figure 5A) to study the expression of 
known targets of oxidative stress involved in the regulation of energy metabolism, 
apoptosis and proliferation (Klaunig and Kamendulis, 2004). We did not find relevant 
changes in the content and/or in the phosphorylation status of the serine/threonine 
kinases Akt, c-Jun N-terminal kinase (JNK) and p38 kinase, which play important roles 
in adaptation to stress, inhibition of apoptosis and induction of proliferation (Cairns et 
al., 2011). Likewise, the transcription factor HIF1α was not affected by IF1 expression 
(Figure 5A). Interestingly, overexpression of IF1 triggered the upregulation of the anti-
apoptotic Bcl-xL (Boise et al., 1993) (Figure 5A) whereas silencing of IF1 mediated its 
downregulation (Figure 5A). The changes in Bcl-xL expression occurred in the absence 
of relevant changes in the cellular content of the pro-apoptotic Bax (Figure 5A). The 
transcription factor NFκB regulates a large number of genes related to inflammation, 
cell proliferation and apoptosis (Guha et al., 2010; Karin, 2006) and specifically Bcl-xL 
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(Lee et al., 1999). Therefore, we next studied the putative ROS-mediated activation of 
the NFκB signaling pathway in response to IF1 overexpression.  
Upregulation of IF1 triggers the activation of the NFκB pathway. A significant 
increase in the activity of the NFκB promoter was observed in HCT116 cells treated 
with H2O2 or overexpressing IF1 (Figure 5B). Interestingly, the enhanced activity of 
NFκB promoter was obliterated in the presence of the mitochondrial ROS scavenger 
MQ (Figure 5B), indicating the relevance of ROS signaling for IF1-mediated activation 
of NFκB.  
An increased activity of NFκB was further confirmed by assessing the 
expression of some of its targeted genes (Figure 5C). Significantly, IF1 overexpression 
triggered the downregulation of NFKBIA, the IκBα inhibitor of NFκB, and of the 
signaling molecules and receptors involved in the innate immune response such as 
complement factor B (CFB), interleukin 8 (IL8), the toll-like receptor 7 (TLR7) and the 
toll-like receptor adaptor molecule 1 (TICAM1) (Figure 5C). Likewise, IF1 triggered the 
upregulation of NFκB targeted genes such as the mitogen-activated MEK kinase 
(MAP3K1), which integrates cellular responses to mitogenic and metabolic stimuli, as 
well as the transcription factors and co-activators EGR1, c-FOS, STAT1, BCL3 and 
NFKB2 (Figure 5C). Furthermore, IF1 led to the upregulation of the signaling 
molecules (IL and LTA) and receptors (LPAR and, TLR2) that promote proliferation and 
tumor invasion (Figure 5C). Determination of the expression of NFκB targeted genes in 
the presence of the ROS scavenger MQ confirmed for most of them their ROS-
dependent (inhibition/activation) response (Figure 5C). It should be noted that MQ did 
not revert the IF1-mediated changes in gene expression in those cases where treatment 
with MQ alone induced a significant change compared to controls (Figure 5C). 
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Consistent with the ROS-mediated activation of the NFκB pathway, cells 
overexpressing IF1 showed an increased phosphorylation of the repressor IκBα (Figure 
5D) and the concurrent reduction of its cellular content (Figure 5D). The incubation of 
the cells with the ROS scavenger MQ minimized IκBα phosphorylation and its 
downregulation (Figure 5D).  
ROS mediate transcriptional activation of Bcl-xL. Next, we studied the 
mechanisms controlling the cellular accumulation of Bcl-xL in response to IF1-
mediated ROS signaling (Figure 6A-C). The overexpression of IF1 triggered the 
transcriptional activation of the Bcl-xL promoter (Figure 6B) resulting in the cellular 
accumulation of Bcl-xL mRNA (Figure 6C) and protein content (Figure 6A). 
Quenching the IF1-mediated ROS signal abolished transcriptional activation of Bcl-xL 
(Figure 6B) and the accumulation of Bcl-xL at both the protein (Figure 6A) and mRNA 
levels (Figure 6C). Interestingly, and consistent with the lack of changes in Bax content 
(Figure 5A), we observed no changes in Bax promoter activity by IF1 overexpression 
(Figure 6D), suggesting that the IF1-mediated resistance to cell death is accomplished 
by increasing the cellular content of Bcl-2 anti-apoptotic members.  
Mitochondrial ROS signaling links IF1 with proliferation and cell survival. To 
establish a link between IF1-mediated ROS production and cellular proliferation and the 
prevention of cell death, the effect of quenching the ROS signal was studied in 
proliferation (Figure 7A) and cell death after exposure to STS (Figure 7B). Treatment of 
IF1-overexpressing cells with MQ inhibited the positive effect of IF1 on cellular 
proliferation (Figure 7A), suggesting that it represents a ROS-mediated response. As 
shown previously (Figure 3A), IF1 overexpression significantly reduced cell death after 
STS treatment (Figure 7B) while quenching the IF1-induced ROS signal with MQ 
reverted this effect (Figure 7B). Moreover, the silencing of Bcl-xL in IF1 
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overexpressing cells resulted in a large increase in cell death (Figure 7C), further 
supporting that IF1-mediated up-regulation of Bcl-xL is critical for restraining apoptosis 
in this situation. 
IF1 mediates similar signaling events in SW620 colon carcinoma cells.  The 
overexpression of IF1 in SW620 cells corroborated the role of IF1 in mediating the 
inhibition of oxidative phosphorylation (OSR) and the subsequent production of 
mitochondrial ROS (Supplemental Figure S4). Likewise, IF1 overexpression also 
triggered the ROS-dependent activation of NFκB, of cellular proliferation and 
ameliorated STS-induced cell death in SW620 cells (Supplemental Figure S4). 
Consistently, quenching the IF1-induced ROS signal with MQ reverted these effects 
(Supplemental Figure S4), strongly supporting the essential role of IF1 in retrograde 
signaling the oncogenic phenotype in colon cancer. 
 
 
Discussion 
 The switch from oxidative phosphorylation to glycolysis is a metabolic feature 
of proliferating cells. Consistently, human carcinomas show downregulation of the H+-
ATP synthase concurrently with the induction of enzymes of glycolysis (Cuezva et al., 
2002; Willers and Cuezva, 2011). Moreover, carcinomas have an additional strategy to 
promote the metabolic switch required for proliferation that is mediated by upregulation 
of IF1 (Sanchez-Cenizo et al., 2010). Indeed, here we show that IF1 overexpression in 
colon cancer cells inhibited the activity of the H+-ATP synthase and promoted the 
upregulation of aerobic glycolysis. Conversely, siRNA-mediated silencing of IF1 
triggered an increase in the activity of the H+-ATP synthase and the downregulation of 
aerobic glycolysis. The inhibition of oxidative phosphorylation and subsequent 
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mitochondrial hyperpolarization have further consequences in cellular homeostasis by 
generating a ROS signal (Figure 7D). ROS activate the canonical NFκB pathway, which 
finally signals to the nucleus the activation of proliferation and the evasion of cell death 
(Figure 7D). Since all human breast, colon and lung carcinomas ((Sanchez-Cenizo et al., 
2010), and unpublished data) show a very large increase in the mitochondrial content of 
IF1 we support that IF1 is mastering the epigenetic acquisition of several hallmarks of 
the oncogenic phenotype via the regulation of energy metabolism in mitochondria.  
Inhibition of the black flow of H+ generated by respiration into the mitochondrial 
matrix promotes an increase in ΔΨm (Brand et al., 2004). In fact, oligomycin that binds 
the proton channel of the H+-ATP synthase promotes mitochondrial hyperpolarization 
(Sanchez-Cenizo et al., 2010). Similar findings are obtained when cancer (Figure 1C) 
and non-cancer (Sanchez-Cenizo et al., 2010) cells overexpress IF1. Cancer cells 
display unusually high ΔΨm (Modica-Napolitano and Singh, 2002) and a direct 
consequence of mitochondrial hyperpolarization is the production of superoxide radical 
(Brand et al., 2004). Consistently, cancer cells are known to have higher basal levels of 
ROS (Szatrowski and Nathan, 1991). In agreement with these findings, we have 
observed that the overexpression of IF1 triggers mitochondrial hyperpolarization, a 
higher basal production of superoxide radical as well as increased carbonylation of 
cellular proteins. Therefore, we suggest that the high ΔΨm and ROS levels observed in 
cancer cells most likely result from the IF1-mediated inhibition of the H+-ATP synthase 
due to the high expression level of IF1 observed in most cancer cells (Sanchez-Cenizo 
et al., 2010). In this regard, it has been shown that IEX-1, a stress-inducible gene 
involved in IF1 degradation, also suppresses the production of reactive oxygen species 
(Shen et al., 2009).  
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Previous studies have shown in carcinomas with mutations in mtDNA or in Kras 
(Ishikawa et al., 2008; Weinberg et al., 2010) that an enhanced mitochondrial activity is 
required to generate the ROS involved in tumorigenicity. In contrast, the ROS-mediated 
oncogenic function of IF1 is exerted by inhibition of the H+-ATP synthase and thus by 
restraining the bioenergetic activity of mitochondria. Since IF1 is highly up-regulated in 
breast, colon and lung carcinomas ((Sanchez-Cenizo et al., 2010) and unpublished data) 
it is likely that its mechanism of action could be generalized to all these tumors. We 
suggest, in light of recent findings (Mullen et al., 2011), that carcinomas with IF1-
limited oxidative phosphorylation could also have glutamine-dependent reductive 
carboxylation as a major pathway for citrate formation. 
Mitochondrial retrograde signaling is a pathway of communication from the 
mitochondria to the nucleus that influences many adaptive responses under both normal 
and pathophysiological conditions (Butow and Avadhani, 2004). It has been 
documented that the collapse of ΔΨm triggers a Ca2+-mediated signaling cascade that 
leads to the activation of the Ca2+-responsive phosphatase calcineurin, which regulates 
the activity of several transcription factors including the NFκB pathway (Guha et al., 
2010). Although we cannot exclude Ca2+-signaling in cells overexpressing IF1, its 
participation seems unlikely due to the transient nature of Ca2+ signals and to the 
opposite changes noted in ΔΨm. Likewise, the absence of IF1-mediated changes in 
HIF1α expression supports the idea that mitochondrial ROS signaling might activate a 
cellular adaptation program unrelated to the hypoxia associated pathway (Weinberg et 
al., 2010). We believe that sustained retrograde ROS signaling by mitochondrial 
hyperpolarization in non-hypoxic conditions explains the adaptive phenotype of cells 
overexpressing IF1. Indeed, we show that quenching the mitochondrial production of 
superoxide radical prevented both the proliferative and pro-survival activities of IF1. 
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The effect of ROS on cell fate depends on the level at which ROS are present 
(Hamanaka and Chandel, 2010). Interestingly, the ROS-mediated activation of the 
NFκB pathway triggered by IF1 appears not to correlate with the induction of the 
antioxidant defense because we observed a higher basal level of oxidation of cellular 
proteins, suggesting that the ROS-signaling event is of moderate intensity and able to 
promote proliferation and survival. Consistent with a mild IF1-mediated ROS signal, we 
observe no relevant changes in cellular hydrogen peroxide content and in the 
GSH/GSSG ratio. These observations suggests that cancer cells have additional 
strategies to overcome the effects of excessive ROS signaling, which might be related to 
the expression of uncoupling proteins in their mitochondria (Brand et al., 2004).  
The transcription factor NFκB has emerged as a crucial regulator of cellular 
adaptive responses involving proliferation and survival (Karin, 2006). The NFκB 
pathway is also involved in the regulation of the immune response (Vesely et al., 2011) 
and in some situations promotes the activation of mitochondrial respiration (Mauro et 
al., 2011). Alterations in these activities contribute to cancer development and 
progression. ROS can interact with NFκB at various places within its signaling pathway 
(Morgan and Liu, 2011). One main pathway that cross-talks with NFκB and ROS is 
JNK. However, we observed no discernible changes in JNK at both the protein and 
mRNA levels as well as in the extent of phosphorylation of the kinase. It has been 
argued that mitochondrial retrograde signaling regulates both the canonical and non-
canonical NFκB pathways (Guha et al., 2010). Our data demonstrate that IF1 mediates 
the activation of the canonical pathway because we observe the phosphorylation and 
cellular reduction of the repressor IκBα. Moreover, we show that quenching 
mitochondrial ROS production abolished NFκB activation by preventing IκBα 
phosphorylation and degradation.  
 15
It is well established that oxidative phosphorylation is required for efficient 
execution of cell death (Dey and Moraes, 2000; Matsuyama et al., 1998; Santamaria et 
al., 2006). In fact, the inhibition of the activity of the H+-ATP synthase by oligomycin 
delays apoptosis in response to different stimuli (Matsuyama et al., 1998; Santamaria et 
al., 2006). Fragmentation, swelling and the release of apoptogenic molecules from 
mitochondria are primary events in signaling the execution of cell death after STS 
treatment (Santamaria et al., 2006). Accordingly, we observe that IF1-mediated 
inhibition of the activity of H+-ATP synthase also contributed to ameliorating 
mitochondrial swelling, delaying the release of AIF from mitochondria and the 
execution of apoptosis, very much mimicking the effects of oligomycin (Santamaria et 
al., 2006). In addition to the inhibition of the activity of the H+-ATP synthase by IF1, 
human carcinomas decrease the activity of oxidative phosphorylation by promoting the 
downregulation of the expression of the H+-ATP synthase (Cuezva et al., 2002; Li et al., 
2010). These findings indicate that active oxidative phosphorylation functionally 
operates as a tumor suppressor, in agreement with previous suggestions (for review see 
(Cuezva et al., 2009)) and recent findings (D'Errico et al., 2011).  
The IF1-mediated activation of NFκB promotes the expression of anti-apoptotic 
genes such as Bcl-xL, which is an additional strategy of the tumor cell to evade 
immunosurveillance (Vesely et al., 2011). Accordingly, IF1 signaling to the NFκB 
pathway promoted the repression of the expression of genes involved in the innate 
immune response (Figure 5). Likewise, IF1-mediated NFκB activation was observed to 
lead to the upregulation of mitogenic genes and genes involved in proliferation and 
tumor invasion (Figure 5). Thus, IF1-signaling to the nucleus promotes the activation of 
multiples pathways for the perpetuation of the cancer cell. Therefore, IF1 could be 
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envisioned as the molecular switch in the cancer cell that turns mitochondrial activity 
from a tumor suppressor into a tumor promoter.  
The number of cancers related with genetic alterations of mitochondria are very 
limited (Frezza and Gottlieb, 2009). However, the impact of cancer genes in energy 
metabolism has been amply demonstrated (Cuezva et al., 2009; Hu et al., 2011; Li et al., 
2005; Vander Heiden et al., 2009). Although the role of mitochondrial activity in cancer 
cells has been questioned (Dang, 2010; Funes et al., 2007; Li et al., 2005) the study of 
large cohorts of most prevalent human carcinomas sustain the alteration of the 
bioenergetic function of mitochondria (Cuezva et al., 2002; Cuezva et al., 2009; Lopez-
Rios et al., 2007). We should emphasize that mitochondrial dysfunction in tumors is not 
“irreversible” (Michelakis et al., 2008; Sanchez-Arago et al., 2010) because energy 
metabolism depends on many factors that could influence at short- or long-term the 
activity of the enzymes involved (Formentini et al., 2010). The over-expression of IF1 
in human carcinomas is an additional epigenetic factor that contributes to the peculiar 
energy metabolism of mitochondria in cancer. In fact, IF1 directly promotes the 
acquisition of three hallmarks of the cancer phenotype: (i) the switch in energetic 
metabolism, (ii) increased proliferation and invasion and (iii) the evasion of cell death 
(Figure 7D). We suggest that studies aimed at characterizing the regulation of IF1 
expression will provide profitable targets for therapeutic intervention.  
 
Experimental Procedures 
Cell cultures, transfections and siRNA silencing. Human colorectal carcinoma 
HCT116 and SW620 cells were grown in McCoy’s 5A or RPMI media, respectively. 
HeLa and T47D cells were grown in DMEM and RPMI, respectively. Transfections 
were performed using Lipofectamine and Plus Reagent (Invitrogen™). The plasmids 
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encoding human IF1 and a mitochondrial version of GFP were used (Sanchez-Cenizo et 
al., 2010). Suppression of IF1 (Qiagen S100908075) and Bcl-xL (Qiagen s1922) 
expression was exerted by small interfering RNA (siRNA).  An inefficient siRNA 
sequence, Silencer® Select Negative Control #1 plasmid (Ambion/Applied 
Biosystems), was used as a control. Where indicated, 20 nM of the mitochondrial ROS 
scavenger MQ (Kelso et al., 2001), kindly provided by Dr. Murphy (University of 
Otago, Dunedin, New Zealand), was added to the incubation.  
Determination of aerobic glycolysis and oxygen consumption rates. The initial 
rate of lactate production and the oxygen consumption rates (XF24 Extracellular Flux 
Analyzer, Seahorse Bioscience) were determined (Sanchez-Cenizo et al., 2010).   
Determination of the mitochondrial membrane potential (ΔΨm). Cells were 
incubated with 0.5 µM TMRM+ (Molecular Probes) and processed for flow cytometry 
(Sanchez-Cenizo et al., 2010).  
Determination of ATP.  Cells were incubated for 1 h with or without 100 mM 2-
deoxy-D-glucose and cellular ATP concentrations determined using the ATP 
Bioluminescence Assay Kit CLS II (Roche).  
Assessment of cell growth and invasion. The incorporation of 5-ethynyl-
2′deoxy-uridine (EdU) into cellular DNA was determined using the Click-iT EdU Flow 
Cytometry Assay Kit (Molecular Probes). To quantify cell invasion a QCM invasion 
assay kit (Millipore) was used.   
Cell cycle and cell death assays. Cells were treated with 1µM STS or 10µM 
5FU during 24 h and processed for flow cytometry after propidium iodide staining. 
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Exposure of phosphatidylserine on the cell surface was analyzed using the annexin V-
FITC assay (Sigma-Aldrich) (Sanchez-Arago et al., 2010). 
Western blot and analysis of protein carbonylation. Details of the antibodies 
used in western blots are provided in Supplemental information. For the determination 
of protein carbonylation, the Oxyblot Oxidized Protein Detection kit (Chemicon 
International) was used (Santamaria et al., 2006).  
Determination of promoter activities. Cells were co-transfected with IF1, CDL-
GFP-β-3’UTR (Sanchez-Cenizo et al., 2010) and NFκB, Bcl-xL and Bax promoter 
reporter plasmids (Switchgear Genomics). Luciferase activity was determined with the 
Luciferase Assay System kit (Promega) using a FLUOstar OPTIMA (BMG Labtech) 
plate luminometer.  
Gene expression analysis by qPCR. Reverse transcription reactions were 
performed using 1 μg of total RNA and the High Capacity Reverse Transcription Kit 
(Applied Biosystems). Gene expression analysis was performed using the cDNA on 
Human NFκB Signaling Pathway RT²Profiler PCR Array plates (SABiosciences) and 
real-time polymerase chain reaction (PCR) with an ABI PRISM 7900HT SDS (Applied 
Biosystem) and Power Sybr Green PCR Master Mix (Applied Biosystems). Bcl-xL 
expression was assessed using the following primers: F, 5’-
AGCCTTGGATCCAGGAGAA-3’ and R, 5’-AGCGGTTGAAGCGTTCCT-3’ as 
detailed (Ortega et al., 2010). 
Statistical Analysis. Statistical analyses were performed using a two-tailed 
Student’s t-test. ANOVA with post hoc Dunnett’s test were used for multiple 
comparisons to the control, using the SPSS 17.0 software package. The results shown 
are means ± SEM. A P < 0.05 was considered statistically significant. 
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Figure Legends 
Figure 1. IF1 is upregulated in colon cancer and regulates energy metabolism. A 
and B, Representative immunohistochemistries of IF1 expression in human colon 
carcinomas (A) and in normal tissue (B). Bars, 35 μm. C-H, HCT116 cells transfected 
with CDL-GFP-β-3’UTR were co-transfected with control (CRL and siCRL, closed 
bars), IF1 plasmid (IF1, open bars) or siIF1 siRNA (siIF1, grey bars) to regulate the 
expression of IF1. C, Representative blots of IF1 and β-F1-ATPase (β-F1) expression. 
The mitochondrial content of IF1 is shown by the IF1/β-F1 ratio. Bars are the mean ± 
s.e.m. of four experiments. D, The oligomycin sensitive respiratory (OSR) rates were 
determined in a XF24 Seahorse equipment after the addition of 6µM OL. Bars are the 
mean ± s.e.m. of three experiments. E, The mitochondrial membrane potential (ΔΨm) 
was determined in cells expressing gfp. Bars are the mean ± s.e.m. of three experiments. 
F, Rates of aerobic glycolysis. Bars are the mean ± s.e.m. of three experiments.  G and 
H, Cellular ATP concentrations were determined in the absence (G) or presence (H) of 
100 mM 2-deoxy-D-glucose (2DG) for 1 h. The effect of 6 μM oligomycin (OL) is 
shown (H). Bars in G and H are the mean ± s.e.m. of three experiments. See also 
Supplemental Figure S4-A. 
 
Figure 2. IF1 triggers cellular proliferation, invasion and survival. HCT116 cells 
transfected with CDL-GFP-β-3’UTR were co-transfected with control (CRL and siCRL, 
closed bars), IF1 plasmid (IF1, open bars) or siIF1 siRNA (siIF1, grey bars) to regulate 
the expression of IF1. A, Cellular proliferation was assessed by the incorporation of 
EdU into cellular DNA. Black (CRL and siCRL) and grey (IF1 and siIF1) traces are 
shown. B, Cellular invasion was assessed with the QCM cell invasion assay. In A and 
B, the panels show representative data from overexpression (IF1) and silencing (siIF1) 
 25
experiments.  Bars are the mean ± s.e.m. of four experiments. C and D, Twenty four h 
after transfection with IF1 (C) or siIF1 (D), the cells were treated with 1µM STS or 
10µM 5FU. After 24 h of treatment the cells were stained with propidium iodide and the 
green population of cells was analyzed by flow cytometry to evaluate the cell cycle 
(panels). Bars show the percentage of sub-G0 cells. Bars are the mean ± s.e.m. of three 
experiments. See also Supplemental Figure S1. 
 
Figure 3. IF1 modulates the execution of apoptosis. HCT116 (A,B) or HeLa (C) cells 
transfected with CDL-GFP-β-3’UTR were co-transfected with control (CRL and siCRL, 
closed bars), IF1 plasmid (IF1, open bars) or siIF1 siRNA (siIF1, grey bars) to regulate 
the expression of IF1. Twenty four h after transfection with IF1 (A, B) or siIF1 (A, C), 
the cells were treated with 1µM STS. A, After 24 h of treatment the cells were stained 
with annexin V-FITC to evaluate the percentage of apoptotic cell death by flow 
cytometry. Bars show the percentage of apoptosis in transfected cells. The results 
shown are the mean±s.e.m. of five experiments. B and C, At the indicated time after 
STS treatment HCT116 (B) or HeLa (C) cells were processed for AIF immunostaining. 
The loss of the mitochondrial staining of AIF was evaluated in 30 different fields taken 
at 20x magnification per condition. Note the redistribution of AIF into the cytoplasm 
and nucleus in STS-treated cells. The plots show the delayed (B) or accelerated (C) 
release of AIF from mitochondria mediated by IF1 overexpression or its 
downregulation, respectively. The results shown are the mean±s.e.m. Bars, 30 μm. See 
also Supplemental Figure S2. 
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Figure 4. IF1 triggers mitochondrial ROS production. HCT116 cells transfected 
with CDL-GFP-β-3’UTR were co-transfected with control (CRL, closed bars) or IF1 
plasmid (IF1, open bars) in the absence (-) or presence (+) of 20 nM of the 
mitochondrial ROS scavenger MitoQ (MQ). A, The superoxide radical was determined 
by FACS analysis using MitoSox. The data shown are mean±s.e.m. of four experiments. 
B, A representative experiment of the extent of carbonylation of cellular proteins treated 
in the absence (-) or presence (+) of DPNH for the identification of protein carbonyls. 
Protein loading of the samples was verified by western blotting with anti-tubulin 
antibody. The migration of molecular mass markers is indicated to the right. Arrows (to 
the left) identify the migration of the four proteins used in quantification of protein 
carbonylation in the histograms shown in C. The data shown are mean±s.e.m. of three 
experiments. See also Supplemental Figure S3 and Figure S4-B. 
 
Figure 5. IF1-dependent activation of the NFκB pathway. HCT116 cells transfected 
with CDL-GFP-β-3’UTR were co-transfected with control (CRL and siCRL, closed 
bars), IF1 plasmid (IF1, open bars) (A-D) or siIF1 siRNA (siIF1, grey bars) (A) in the 
absence (-) or presence (+) of 20 nM of the mitochondrial ROS scavenger MQ (B, C, 
D). A and D, Cellular proteins were fractionated on SDS-PAGE and processed for 
Western blotting with the indicated primary antibodies. Representative blots of one (A) 
or two different samples (D) per condition tested are shown. The results shown are the 
mean±s.e.m. of three experiments. B, A luciferase reporter plasmid of the NFκB 
promoter was co-transfected and the luciferase activity was determined in cellular 
extracts after 24h transfection. Cells incubated with 10 μM H2O2 were used as positive 
control of the activation of NFκB promoter. The data shown are mean±s.e.m. of five 
experiments. C, The expression of genes of the NFκB pathway was determined by 
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qPCR in RNA extracted from cells treated as indicated using the RT²Profiler PCR 
Array. The schematic summarizes some of the genes up-regulated (closed boxes), non-
affected (grey boxes) and downregulated (open boxes) by the overexpression of IF1. 
The data shown are mean±s.e.m. of four experiments. See also Supplemental Figure S4-
C. 
 
Figure 6. ROS-mediated transcriptional activation of Bcl-xL. HCT116 cells 
transfected with CDL-GFP-β-3’UTR were co-transfected with control (CRL, closed 
bars) or IF1 plasmid (IF1, open bars) in the absence (-) or presence (+) of 20 nM of the 
mitochondrial ROS scavenger MQ (MQ). A, A representative Western blot of control 
(CRL) and IF1 over-expressing (IF1) cells shows the ROS-dependent up-regulation of 
Bcl-xL in response to IF1 overexpression. Two different samples per condition tested 
are shown. The data shown are mean±s.e.m. of four experiments. B and D, Cells were 
co-transfected with luciferase reporter plasmids of the Bcl-xL (B) or Bax (D) promoters 
and the luciferase activity determined. The data shown are mean±s.e.m. of four 
experiments. C, Bcl-xL mRNA expression was determined by reverse transcription and 
quantitative polymerase chain reaction (qPCR). The data shown are mean±s.e.m. of 
three experiments.  
 
Figure 7. IF1 mediates metabolic adaptation, cellular proliferation and survival. 
HCT116 cells transfected with CDL-GFP-β-3’UTR were co-transfected with control 
(CRL, closed bars) or IF1 plasmid (IF1, open bars) in the absence (-) or presence (+) of 
20 nM of the mitochondrial ROS scavenger MQ (MQ). A, Cellular proliferation was 
assessed by the incorporation of EdU into DNA by FACS analysis. Upper and lower 
panels show representative data from control (CRL) and IF1-overexpression (IF1) 
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experiments, respectively. Traces: pink (CRL), blue (CRL+MQ), brown (IF1) and green 
(IF1+MQ). The results shown are the mean±s.e.m. of three experiments. B, Cells were 
treated with 1µM STS. Twenty four h post-treatment the percentage of sub-G0 cells was 
determined by flow cytometry. The data shown are mean±s.e.m. of three experiments.  
C, IF1-transfected cells were co-transfected with control (siCRL) or Bcl-xL (siBcl-xL) 
siRNA and processed as in B.  The data shown are mean±s.e.m. of three experiments.  
D, The schematic summarizes the IF1-mediated inhibition of the synthase activity of the 
mitochondrial H+-ATP synthase and the further activation of aerobic glycolysis in 
cancer cells. Inhibition of the H+-ATP synthase also triggers mitochondrial 
hyperpolarization (↑ΔΨ) and the subsequent increase in superoxide radical production 
(ROS). The increase in cellular ROS leads to the activation of the NFκB pathway which 
is involved in activation of cellular proliferation and survival by the inhibition of cell 
death. Metabolic reprogramming to aerobic glycolysis (Warburg Effect) is also known 
to confer a cellular phenotype that offers advantages for proliferation and minimizes the 
chances of cell death. See also Supplemental Figure S4-D and Figure S4-E. 
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